Haverford Trust Co Has $247,000 Holdings in Haleon plc (NYSE:HLN)

Haverford Trust Co boosted its position in shares of Haleon plc (NYSE:HLN) by 5.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,842 shares of the company’s stock after acquiring an additional 1,233 shares during the period. Haverford Trust Co’s holdings in Haleon were worth $247,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Sierra Ocean LLC acquired a new position in shares of Haleon during the 4th quarter worth about $26,000. Versant Capital Management Inc lifted its holdings in shares of Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Haleon in the fourth quarter valued at approximately $35,000. Toronto Dominion Bank grew its stake in shares of Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after acquiring an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management bought a new position in Haleon during the fourth quarter worth $39,000. 6.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on HLN. HSBC reissued a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Finally, Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Six investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.95.

Haleon Stock Down 0.9 %

NYSE HLN opened at $10.05 on Wednesday. Haleon plc has a 1-year low of $7.99 and a 1-year high of $10.80. The company has a market capitalization of $45.50 billion, a price-to-earnings ratio of 29.56, a PEG ratio of 2.82 and a beta of 0.25. The stock’s 50 day moving average is $9.89 and its two-hundred day moving average is $9.88. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Equities analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This represents a dividend yield of 1.6%. This is a boost from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.